Xenon Pharmaceuticals (XENE) Projected to Post Earnings on Thursday

Xenon Pharmaceuticals (NASDAQ:XENE) is projected to release its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of ($1.20) per share for the quarter. Investors may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Friday, February 27, 2026 at 4:00 PM ET.

Xenon Pharmaceuticals Stock Performance

Shares of XENE stock opened at $42.51 on Thursday. The stock’s 50 day simple moving average is $42.48 and its 200 day simple moving average is $40.58. Xenon Pharmaceuticals has a twelve month low of $26.74 and a twelve month high of $46.60. The company has a market capitalization of $3.29 billion, a price-to-earnings ratio of -10.93 and a beta of 0.96.

Insider Activity

In related news, CEO Ian Mortimer sold 40,000 shares of the stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $44.43, for a total value of $1,777,200.00. Following the transaction, the chief executive officer directly owned 6,000 shares in the company, valued at $266,580. This represents a 86.96% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders sold a total of 65,302 shares of company stock worth $2,924,128 over the last quarter. Corporate insiders own 4.07% of the company’s stock.

Hedge Funds Weigh In On Xenon Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in XENE. Virtus Investment Advisers LLC boosted its holdings in shares of Xenon Pharmaceuticals by 74.0% in the 4th quarter. Virtus Investment Advisers LLC now owns 6,037 shares of the biopharmaceutical company’s stock valued at $271,000 after buying an additional 2,568 shares during the last quarter. Amundi bought a new stake in Xenon Pharmaceuticals during the fourth quarter worth $207,000. Magnetar Financial LLC acquired a new stake in Xenon Pharmaceuticals in the fourth quarter valued at $231,000. Cibc World Markets Corp bought a new position in shares of Xenon Pharmaceuticals in the 4th quarter valued at about $225,000. Finally, PenderFund Capital Management Ltd. acquired a new position in shares of Xenon Pharmaceuticals during the 3rd quarter worth about $275,000. Institutional investors and hedge funds own 95.45% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have issued reports on XENE. Weiss Ratings reiterated a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a research note on Friday, January 9th. Stifel Nicolaus set a $66.00 price target on shares of Xenon Pharmaceuticals in a report on Tuesday, February 10th. JPMorgan Chase & Co. upped their price objective on shares of Xenon Pharmaceuticals from $60.00 to $62.00 and gave the stock an “overweight” rating in a research note on Friday, January 9th. Needham & Company LLC reiterated a “buy” rating and issued a $55.00 target price on shares of Xenon Pharmaceuticals in a research note on Tuesday, November 4th. Finally, Royal Bank Of Canada increased their price target on Xenon Pharmaceuticals from $55.00 to $58.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 4th. Two investment analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Xenon Pharmaceuticals presently has an average rating of “Buy” and an average target price of $54.73.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.